pre-IPO PHARMA

COMPANY OVERVIEW

Stimunity is a preclinical-stage startup company which develops best-in-class drugs on the STING pathway to activate the innate immune system. Our drugs stimulate patients' immune system to fight back infectious pathogens or cancer. Our technology is based on high level academic research work from prestigious institutions: Institut Curie, the French National Institute of Health and Medical Research (Inserm) and University of Oxford.


LOCATION

  • Paris, , France
  • Paris, , France

  • THERAPEUTIC AREAS

  • Infectious Disease
  • Oncology

  • WEBSITE

    https://stimunity.com


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    portage-biotech

    PRESS RELEASES


    Apr 25, 2022

    Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity


    May 11, 2020

    Portage Makes Additional Investment in Stimunity S.A.S, a Paris-Based Cancer Immunotherapy Company.


    Mar 25, 2019

    Portage makes additional investment in Stimunity S.A, a Paris-based cancer immunotherapy company.


    Jun 4, 2018

    Portage provides update on its associate, Stimunity S.A, a Paris-based cancer immunotherapy company


    For More Press Releases


    Google Analytics Alternative